Journal Article10.1128/CMR.12.1.40
Current and Emerging Azole Antifungal Agents
1.1K
TL;DR: Present and future uses of the currently available azole antifungal agents in the treatment of systemic and superficial fungal infections are described and a brief overview of the current status of in vitro susceptibility testing and the growing problem of clinical resistance to the azoles is provided.
read more
Abstract: Major developments in research into the azole class of antifungal agents during the 1990s have provided expanded options for the treatment of many opportunistic and endemic fungal infections. Fluconazole and itraconazole have proved to be safer than both amphotericin B and ketoconazole. Despite these advances, serious fungal infections remain difficult to treat, and resistance to the available drugs is emerging. This review describes present and future uses of the currently available azole antifungal agents in the treatment of systemic and superficial fungal infections and provides a brief overview of the current status of in vitro susceptibility testing and the growing problem of clinical resistance to the azoles. Use of the currently available azoles in combination with other antifungal agents with different mechanisms of action is likely to provide enhanced efficacy. Detailed information on some of the second-generation triazoles being developed to provide extended coverage of opportunistic, endemic, and emerging fungal pathogens, as well as those in which resistance to older agents is becoming problematic, is provided.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Synthesis, and antiprotozoal and antibacterial activities of S-substituted 4,6-dibromo- and 4,6-dichloro-2-mercaptobenzimidazoles.
Mariola Andrzejewska,Lilián Yépez-Mulia,Amparo Tapia,Roberto Cedillo-Rivera,Agnieszka E. Laudy,Bohdan Starościak,Zygmunt Kazimierczuk +6 more
TL;DR: Among Gram-negative bacteria used, Stenotrophomonas maltophilia and Bordetella bronchiseptica were most sensitive and Pseudomonas aeruginosa was most resistant to the new benzimidazole derivatives (all MICs >400microg/ml).
Strategies for the prevention of microbial biofilm formation on silicone rubber voice prostheses.
TL;DR: An overview of the different approaches investigated to date and future perspectives to reduce the frequent replacements of voice prostheses in laryngectomized patients through microbial biofilm retardation is presented and discussed.
Antifungal Susceptibilities of Clinical Isolates of Candida Species, Cryptococcus neoformans, and Aspergillus Species from Taiwan: Surveillance of Multicenter Antimicrobial Resistance in Taiwan Program Data from 2003
Po-Ren Hsueh,Yeu-Jun Lau,Yin Ching Chuang,Jen Hsien Wan,Wen Kuei Huang,Jainn Ming Shyr,Jing Jou Yan,Kwok Woon Yu,Jiunn Jong Wu,Wen Chien Ko,Yi Chueh Yang,Yung Ching Liu,Lee-Jene Teng,Cheng-Yi Liu,Kwen-Tay Luh +14 more
TL;DR: Voriconazole was the most potent agent against the fungal isolates tested, including fluconazole- and amphotericin B-nonsusceptible strains, including isolates with increased resistance to amphoteric in B and itraconazole.
Synthesis and Biological Evaluation of Some Novel S-β-D-Glucosides of 4-Amino-5-alkyl-1,2,4-triazole-3-thiones Derivatives.
TL;DR: A novel series of 3-S-β-D-glucosides-4-arylideneamino-5-alkyl-1,2,4-triazoles designed and synthesized by reaction of 4-amino -5-alksyl-4H-1-2, 4triazole-3-thiol Schiff bases have been screened for their in vitro antibacterial and antifungal activities against two Gram-positive bacteria and fungi.
An Aptamer-Based Biosensor for the Azole Class of Antifungal Drugs.
Gregory Wiedman,Yanan Zhao,Arkady Mustaev,Jinglei Ping,Ramya Vishnubhotla,A. T. Charlie Johnson,David S. Perlin +6 more
- 30 Aug 2017
TL;DR: This aptamer and the supporting sensing platform provide a valuable tool for therapeutic drug monitoring of patients with invasive fungal infections, and is the first aptamer directed toward the azole class of antifungal drugs and a functional biosensor for these drugs.
References
•Book
Principles and Practice of Infectious Diseases
Gerald L. Mandell,R. Gordon Douglas,John E. Bennett +2 more
- 01 Mar 1989
TL;DR: This updated and expanded edition now offers 297 chapters that cover the basic principles of diagnosis and management, major clinical syndromes, all important pathogenic microbes and the diseases they cause, plus a number of specialised topics useful to the practitioner.
14.4K
National Committee for Clinical Laboratory Standards.
TL;DR: Many members of the Academy of Pediatrics seem to be generally unaware of the fact that the Academy has participated for ten years in a very interesting and valuable organization, the National Committee for Clinical Laboratory Standards (NCCLS).
14.1K
Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.
TL;DR: This review summarizes the factors that contribute to antifungal drug resistance on three levels: clinical factors that result in the inability to successfully treat refractory disease; cellular factors associated with a resistant fungal strain; and molecular factors that are ultimately responsible for the resistance phenotype in the cell.
1.4K
The Merck Index
TL;DR: The Merck Index of Chemicals and Drugs is an encyclopedia for the Chemist, Pharmacist, Physician and Allied Professions and thumb-indexed, 8 dollars.
1.3K